Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 17/20 | 0.57 |
| ▸ | FNTB | P49356 | 17/20 | 0.57 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6583199 | 0.91 | FNTA (0.61) | FNTAFNTBPGGT1B | |
| SCHEMBL6584893 | 0.84 | FNTA (0.64) | FNTAFNTBPGGT1B | |
| SCHEMBL6587157 | 0.78 | FNTA (0.66) | FNTAFNTBPGGT1BCYP3A4 | |
| (S)-Tipifarnib SCHEMBL4429738 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL22772860 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL23633189 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL29371885 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL21544535 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| Tipifarnib SCHEMBL8097 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 | |
| (S)-Tipifarnib SCHEMBL30436988 | 0.76 | FNTA (0.80) | FNTAFNTBPGGT1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1420015-A1 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES S.A.S. (FR) | 2004-05-19 | — | — | EP | disclosed |
| EP-1097150-B1 | IMIDAZOLYL DERIVATIVES | CONSEILS DE RECH SET D APPLIC (FR) | 2004-03-24 | — | — | EP | disclosed |
| US-20040002531-A1 | Imidazolyl derivatives | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTEFIQUES, S.A.S., A FRANCE CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-6509336-B1 | Prenyl transeferase inhibitors | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2003-01-21 | — | — | US | disclosed |
| US-20030004342-A1 | Imidazolyl derivatives | BIOMEASURE, INC., A MASSACHUSETTS CORPORATION | 2003-01-02 | — | — | US | disclosed |
| US-6420555-B1 | IMIDAZOLE DERIVATIVES PRENYL TRANSFERASE INHIBITORS. | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004342-A1 | Imidazolyl derivatives | TPI1, BCHE, CYP51A1 | FNTA 51/4885FNTB 184/4885PGGT1B 1091/4885 |
| US-20040002531-A1 | Imidazolyl derivatives | TPI1, BCHE, CYP51A1 | FNTA 51/4885FNTB 184/4885PGGT1B 1091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.